Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies
暂无分享,去创建一个
[1] P. Dugel,et al. Complement cascade inhibition in geographic atrophy: a review , 2022, Eye.
[2] T. Dryja,et al. Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration , 2021, Investigative ophthalmology & visual science.
[3] Aaron Y. Lee,et al. Evolving treatment patterns and outcomes of neovascular age-related macular degeneration over a decade. , 2021, Ophthalmology. Retina.
[4] J. Maciejewski,et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria , 2020, Haematologica.
[5] B. Joondeph,et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. , 2020, Ophthalmology.
[6] Philip J Rosenfeld,et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. , 2020, Ophthalmology.
[7] A. Urtti,et al. Establishment of an In Vitro-In Vivo Correlation for Melanin Binding and the Extension of the Ocular Half-Life of Small Molecule Drugs. , 2019, Molecular pharmaceutics.
[8] P. Mattei,et al. Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs. , 2018, Journal of medicinal chemistry.
[9] P. Hughes,et al. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations , 2018, Pharmaceutical Research.
[10] A. Urtti,et al. Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[11] Srinivas R. Sadda,et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials , 2018, JAMA ophthalmology.
[12] Mary Joseph,et al. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches☆ , 2018, Advanced drug delivery reviews.
[13] A. Urtti,et al. Implications of melanin binding in ocular drug delivery☆ , 2017, Advanced drug delivery reviews.
[14] A. Urtti,et al. Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] Paul Mitchell,et al. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. , 2017, Ophthalmology.
[16] B. Yaspan,et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration , 2017, Science Translational Medicine.
[17] Ursula Schmidt-Erfurth,et al. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET , 2017, Retina.
[18] A. Urtti,et al. Pharmacokinetic aspects of retinal drug delivery , 2017, Progress in Retinal and Eye Research.
[19] Guangwei Yang,et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome , 2016, Haematologica.
[20] Shusheng Wang,et al. Current therapeutic developments in atrophic age-related macular degeneration , 2015, British Journal of Ophthalmology.
[21] A. Rimpelä. Ocular melanin binding of drugs: in vitro binding studies , 2014 .
[22] Kang Zhang,et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. , 2014, Ophthalmology.
[23] U. Schraermeyer,et al. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes , 2014, British Journal of Ophthalmology.
[24] Cynthia A. Toth,et al. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. , 2013, JAMA.
[25] P. Coffey,et al. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. , 2013, Investigative ophthalmology & visual science.
[26] 山城 健児. Age-Related Eye Disease Study 2 (特集 臨床において必要なサプリメントの知識) , 2012 .
[27] K. Wakamatsu,et al. Structure of Melanins , 2011 .
[28] P. Heiduschka,et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. , 2007, Investigative ophthalmology & visual science.
[29] K. Wakamatsu,et al. Comparisons of the Structural and Chemical Properties of Melanosomes Isolated from Retinal Pigment Epithelium, Iris and Choroid of Newborn and Mature Bovine Eyes¶ , 2005, Photochemistry and photobiology.
[30] E. Solon,et al. Methods determining phosphor imaging limits of quantitation in whole-body autoradiography rodent tissue distribution studies affect predictions of 14C human dosimetry. , 2001, Journal of pharmacological and toxicological methods.
[31] H. Kolbe,et al. Technical validation of radioluminography systems. , 2000, Regulatory toxicology and pharmacology : RTP.
[32] K. Heimann,et al. Current understanding on the role of retinal pigment epithelium and its pigmentation. , 1999, Pigment cell research.
[33] P. Zane,et al. Physicochemical Factors Associated with Binding and Retention of Compounds in Ocular Melanin of Rats: Correlations Using Data from Whole-Body Autoradiography and Molecular Modeling for Multiple Linear Regression Analyses , 1990, Pharmaceutical Research.
[34] N. Lindquist,et al. Accumulation of Chorio-retinotoxic Drugs in the Foetal Eye , 1970, Nature.
[35] A. M. Potts. THE REACTION OF UVEAL PIGMENT IN VITRO WITH POLYCYCLIC COMPOUNDS. , 1964, Investigative ophthalmology.
[36] Jason A. Wiles,et al. Discovery and Development of the Oral Complement Factor D Inhibitor ACH-4471. , 2019, Current medicinal chemistry.
[37] K. Gadde,et al. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Clinical utility of phentermine/topiramate (QsymiaTM) combination for the treatment of obesity , 2013 .
[38] A. Mitra,et al. Ocular drug delivery. , 2010, The AAPS journal.
[39] Jennifer I. Lim,et al. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.
[40] R. Ings,et al. The melanin binding of drugs and its implications. , 1984, Drug metabolism reviews.